Highest-materiality recent filing
ProKidney Q2 2026 loss $46.4M, cash $181.6M; PROACT 1 interim enrollment complete
Completed enrollment for PROACT 1 accelerated approval analysis (~320 pts); topline eGFR slope results expected Q2 2027.
ProKidney Corp. announces 2026 annual meeting results; three directors elected
Stockholders elected William F. Doyle, Alan M. Lotvin, and Brian J.G. Pereira to three-year board terms.
ProKidney Q1 net loss $42.6M; Phase 3 PROACT 1 enrollment on track for mid-2026
Net loss $42.6M for Q1 2026; cash & equivalents $224.9M supporting operations into mid-2027.
Net loss $151.6M in 2025 vs $163.3M in 2024; no revenue as pre-revenue cell therapy company.
ProKidney updates PROACT 1 enrollment target to ~470; confirmatory readout now H2 2029
Enrollment target increased to ~470 subjects in Phase 3 PROACT 1 (REGEN-006) study.
ProKidney updates investor presentation; no financial details disclosed
Company posted updated investor presentation on January 12, 2026.
Q3 net loss before noncontrolling interest $35.8M vs $41.1M YoY; R&D expenses $26.8M.
ProKidney enters agreement to sell Greensboro property for $19.1M cash
Sale of real property in Greensboro, NC to Northpoint Development, LLC for approx. $19.1M cash.
FDA confirmed eGFR slope as surrogate endpoint for accelerated approval of rilparencel; topline data from PROACT 1 expected Q2 2027.
ProKidney completes domestication from Cayman Islands to Delaware, effective July 1, 2025
Each Cayman Class A and B ordinary share converted one-for-one into Delaware Class A and B common stock.
ProKidney gains FDA alignment on accelerated approval pathway for rilparencel; topline data Q2 2027
FDA confirmed eGFR slope as surrogate endpoint for accelerated approval of rilparencel in CKD with type 2 diabetes.
ProKidney enters new $200M ATM equity facility with Jefferies, terminates prior agreement
New Open Market Sale Agreement with Jefferies LLC allows sale of up to $200M of Class A common stock.
eGFR slope improved 78% from -5.8 to -1.3 mL/min/1.73m² per year (p<0.001) in Group 1 (n=24).
ProKidney completes Cayman-to-Delaware domestication effective July 1, 2025
Each Cayman Class A and Class B ordinary share converted 1:1 into Delaware Class A or Class B common stock.
ProKidney Corp. completes redomestication to Delaware, effective July 1, 2025
Shareholders approved the change at the May 29, 2025 Annual General Meeting.
ProKidney shareholders approve reincorporation from Cayman Islands to Delaware
Domestication approved with 227.6M for, 1.1M against; expected completion by end of Q3 2025.
ProKidney Q1 net loss $38M; cash $328.5M; REGEN-007 data due Q2 2025
Net loss before noncontrolling interest was $38.0M for Q1 2025 vs $35.3M in Q1 2024.
ProKidney posts FY2024 net loss of $163.3M; FDA confirms accelerated approval path for rilparencel
Net loss before noncontrolling interest $163.3M in 2024 vs $135.4M in 2023; R&D expenses rose 20% to $127.7M.
ProKidney sells Greensboro, NC property for ~$20.5M in cash; close expected March 2025
Sale of real property in Greensboro, NC for approximately $20.5 million in cash.
ProKidney to acquire two Winston-Salem buildings for $22.5M for rilparencel manufacturing
Purchase price of $22.5 million in cash for two buildings totaling ~180,000 sq ft.
FDA confirms PROACT 1 Phase 3 may support full approval; Q3 cash $406.8M
FDA Type B meeting confirms PROACT 1 Phase 3 could be sufficient for BLA; accelerated approval pathway available using eGFR slope as surrogate endpoint.
ProKidney refocuses Phase 3 program; discontinues PROACT 2, expects topline results Q3 2027
Discontinues ex-U.S. PROACT 2 trial; believes PROACT 1 alone may support FDA approval under RMAT designation.
ProKidney reports Q2 net loss $38.5M, cash $431.5M, restarts Phase 3 trials
Interim Phase 2 REGEN-007 data show kidney function stabilization for 18 months in diabetes/advanced CKD patients.
ProKidney prices upsized $130M offering of 53.7M shares at $2.42 per share
Total offering of 53,719,009 shares at $2.42/share; net proceeds expected ~$136.7M.
ProKidney reports REGEN-007 Phase 2 interim: eGFR stable over 18 months; manufacturing resumed
In Group 1 (n=13), average eGFR change from baseline was -1.3 ml/min/1.73m² at 18 months; subset meeting Phase 3 criteria (n=10) showed -0.6.
ProKidney shareholders elect directors, ratify auditor at 2024 AGM
Jennifer Fox elected to board with 180,074,590 votes for, 1,649,737 against, 218 abstain.
ProKidney provides final Phase 2 RMCL-002 data; specifics not in filing text
Company furnished investor presentation with final data from Phase 2 RMCL-002 clinical trial.
ProKidney reports Q1 net loss $35.3M, cash $329M; Phase 2 data to be presented May 25
RMCL-002 Phase 2 final results to be presented at ERA Congress on May 25, 2024; investor call on May 28.
ProKidney appoints EVP Technical Operations and SVP Global Clinical Operations
Ulrich Ernst appointed EVP Technical Operations; base salary $450,000, target bonus 40%.
ProKidney FY2023 net loss $135.4M; cash $363M; positive Phase 2 data; mfg pause
Net loss before noncontrolling interest $135.4M vs $148.1M in 2022; cash $363.0M, funding into Q4 2025.
ProKidney finalizes separation agreement with ex-CEO Bertram; $620K severance plus benefits
Company pays $620K severance, bonus up to 60% of base salary for 2023 based on scorecard.
ProKidney Corp. finalizes separation agreement with former COO Deepak Jain including $495K severance
Severance pay of $495,000 (12 months base salary) plus eligibility for 2023 bonus up to 45% of base salary.
ProKidney grants supplemental stock option to Chief Legal Officer Todd Girolamo
Option for 234,742 Class A ordinary shares at FMV on March 1, 2024 grant date.
ProKidney releases updated corporate presentation; no specific financial or clinical updates
Company filed an updated investor presentation under Item 7.01 for January 2024.
ProKidney enters $100M ATM equity offering agreement with Jefferies
Agreement with Jefferies to sell up to $100M of Class A ordinary shares at the market.
ProKidney discloses CEO Bruce Culleton's pay: $625k base, 3M share option at $1.69
Base salary of $625,000 per year, eligible for annual bonus with 60% target.
ProKidney terminates COO Deepak Jain without cause, effective Nov 28, 2023
Deepak Jain, Ph.D., COO, was terminated without cause effective November 28, 2023.
ProKidney to repurchase 7.26M shares from two holders for ~$9.5M
Repurchase of 7,256,367 Class A ordinary shares at $1.309/share from SC PIPE Holdings and SC Master Holdings.
ProKidney Q3 net loss widens to $42M; cash runway into Q4 2025
Net loss $42.0M for Q3 2023 vs $33.9M for Q3 2022, driven by higher R&D costs.
ProKidney reports positive Phase 2 data for REACT; narrows Phase 3 enrollment; appoints new CEO
Positive interim Phase 2 data: REACT preserved kidney function up to 30 months in high-risk Stage 3b/4 diabetic CKD patients.
ProKidney updates investor presentation; specific content not disclosed in filing text
Filed updated investor presentation as Exhibit 99.1 on September 11, 2023.
ProKidney reports Q2 2023 net loss of $34.8M; cash at $446.1M
Net loss before noncontrolling interest $34.8M for Q2 2023 vs $22.1M in Q2 2022.
ProKidney closes on $25.5M purchase of 210,000 sq ft Greensboro facility for REACT manufacturing
Paid ~$25.5M cash for 210,000 sq ft facility and 22 acres in Greensboro, NC to support commercial production of REACT cell therapy.
ProKidney elects three directors, ratifies Ernst & Young as auditor
Elected directors William F. Doyle, Alan M. Lotvin, and Brian J.G. Pereira to three-year terms with over 204.6M votes each (>99.9% of votes cast).
Purchase price of ~$25.5M cash for a 210K sq ft facility and 22 acres; expected close by end of June 2023.
ProKidney Q1 net loss $36.9M, cash $463.7M; Phase 2 REACT enrollment complete
Net loss before noncontrolling interest $36.9M vs $67.5M in Q1 2022; R&D spend $25.6M.
ProKidney reports Q4 net loss of $24.6M; cash $490.3M; Phase 3 trials advancing
Cash and cash equivalents $490.3M as of Dec 31, 2022, vs $20.6M year-end 2021.
ProKidney updates investor presentation; no specific new material facts disclosed
Company posted an updated investor presentation on its website and as Exhibit 99.1.
ProKidney CMO Dr. Libbie McKenzie resigns to pursue other opportunities
Dr. Libbie McKenzie resigned as Chief Medical Officer effective February 3, 2023.
ProKidney Corp adopts new Short Term Incentive Performance Plan effective January 16, 2023
Cash bonus plan for all regular employees; target award as a percentage of base salary (up to 150% maximum).
On March 25, 2024, ProKidney Corp. (the “Company”) announced the appointment of Ulrich Ernst, Ph.D. as the Company’s Executive Vice President, Technical Operations effective as of March 25, 2024.
On March 13, 2024 (the “Effective Date”), the Company entered into a Separation Agreement (the “Separation Agreement”) with Dr. Bertram.
On March 13, 2024 (the “Effective Date”), the Company entered into a Separation Agreement (the “Separation Agreement”) with Dr. Jain.
In connection with Mr. Culleton’s appointment to serve as the Company’s Chief Executive Officer, on December 3, 2023, Dr. Culleton and ProKidney, LLC, a Delaware limited company and subsidiary of the Company, entered into an employment agreement, effective as of November 15, 2023 (the “Employment Agreement”), pursuant to which Dr. Culleton will serve as Chief Executive Officer of the Company and its subsidiaries and affiliates.
On November 28, 2023, ProKidney Corp. (“ProKidney” or the “Company”) notified Deepak Jain, Ph.D., Chief Operating Officer of the Company, of the termination of his employment without cause, effective as of the same date, following which Dr. Jain is expected to continue to serve as a consultant to the Company.
the Board approved the appointment of Bruce Culleton, MD, as Chief Executive Officer and as a Class III director of the Company, effective as of the Effective Date.
Dr. Bertram will resign from the Board of Directors (the “Board”) of the Company.
the Board approved the appointment of Bruce Culleton, MD, as Chief Executive Officer and as a Class III director of the Company, effective as of the Effective Date.
the board of directors (the “Board”) of ProKidney Corp. (the “Company”) approved the termination, without cause, of Tim Bertram, Ph.D., Chief Executive Officer of the Company, effective November 15, 2023
On July 11, 2022, the New ProKidney board of directors appointed Jennifer Fox as a member of the board of directors
On September 24, 2021, Uma Sinha PhD was appointed to the board of directors (the “Board”) of Social Capital Suvretta Holdings Corp. III (the “Company”), effective immediately.
On June 29, 2021, in connection with the IPO, Marc Semigran was appointed to the board of directors of the Company
Max materiality 0.85 · Median 0.60 · Most common event other_material